We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Grifols has received approval from the FDA to market Alphanate for treating congenital von Willebrand disease (VWD) in connection with surgery or other invasive procedures.
GlaxoSmithKline (GSK) announced that the FDA has issued an approvable letter for the company's once-daily anticoagulant, Arixtra (fondaparinux sodium), for treating patients with acute coronary syndromes (ACS).
Generex Biotechnology has begun a Phase II clinical trial using its novel peptide vaccine in breast cancer patients in conjunction with the U.S. Military Cancer Institute's Clinical Trials Group under a clinical trial agreement.
Metabasis Therapeutics has completed patient enrollment in its Phase IIb clinical trial for CS-917, a compound being developed by Daiichi Sankyo for the treatment of Type 2 diabetes pursuant to a licensing agreement between the two companies.
Neuren Pharmaceuticals announced that the FDA has accepted its investigational new drug application and authorized the company to proceed with its Phase III trial of Glypromate to prevent cognitive impairment following major cardiac surgery.
NexMed announced that its collaborator, Novartis, has commenced dosing of patients in the Phase III clinical trials for NM100060, a topical treatment for onychomycosis (nail fungus).
Mylan Laboratories announced that Mylan Pharmaceuticals has received final approval from the FDA for its abbreviated new drug application for albuterol sulfate extended-release (ER) tablets, 4 and 8 mg.